ARTICLE | Clinical News
SUPG completes Phase III rubitecan study
February 20, 2001 8:00 AM UTC
SuperGen completed enrollment of more than 400 patients in a U.S. Phase III trial comparing its rubitecan oral topoisomerase I inhibitor to 5-FU in patients with pancreatic cancer who were refractory ...